News
Q2 2025 Earnings Call Transcript August 6, 2025 Operator: Good day, and thank you for standing by. Welcome to the Q2 2025 ...
On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...
The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...
Lilly’s results from an obesity pill study didn’t perform as well as Wall Street expected. It resulted in lower weight loss ...
The news comes days after Novo cut its full-year outlook due to rising competition from copycat compounders, and named a new ...
As announced July 29, Novo Nordisk NVO saw 18% sales growth and 40% operating profit growth at constant currencies in the ...
Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...
34m
Irish Examiner on MSNEli Lilly shares drop after weight-loss 'wonder drug' disappoints
Eli Lilly shares fell as disappointing data on its new weight-loss pill overshadowed strong growth from the company’s current obesity medicine, which helped drive it to raise its yearly profit and ...
US stocks pushed higher on Wednesday amid another batch of corporate earnings and as President Trump's new deadline to impose ...
19h
Al Jazeera on MSNWegovy maker Novo Nordisk warns of layoffs as competition grows
Novo Nordisk’s outgoing CEO, Lars Fruergaard Jorgensen, has warned that layoffs at the Danish pharmaceutical giant could be ...
China has massive unmet medical needs, Mike Doustdar, who took over as CEO of Novo Nordisk today, after previously leading ...
COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk reported second-quarter sales up 18% on Wednesday, below initial analyst ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results